Rubin Jonathan 4

What Happened

• Jonathan Rubin, Senior Vice President and Chief Medical Officer of Supernus Pharmaceuticals (SUPN), received 1,250 restricted stock units (RSUs) that vested on February 25, 2026. Those RSUs were settled into common stock (acquisition recorded at $0.00).
• To satisfy tax withholding requirements, 675 of the vested shares were withheld by the company at a reported per-share value of $50.69, totaling approximately $34,216. The RSU derivative awards were cancelled/settled as part of the vesting (derivative disposition).

Key Details

• Transaction date: February 25, 2026 (Form 4 filed February 26, 2026).
• Award/Acquisition: 1,250 RSUs settled into common stock @ $0.00.
• Tax withholding: 675 shares withheld @ $50.69 each = $34,216 (reported as disposition under code F).
• Derivative disposition: 1,250 RSUs cancelled/settled (code D).
• Net shares received by Rubin from this vesting: 1,250 − 675 = 575 shares (approximate).
• Shares owned after transaction: Not disclosed in the provided filing excerpt.
• Footnotes: F1 — shares withheld to satisfy tax withholding; F2 — each RSU equals one share on vesting; F3 — these RSUs vest in four equal annual installments starting Feb 23, 2024.
• Filing timeliness: Form 4 was filed the next day (Feb 26, 2026), which is timely.

Context

• This was an RSU vesting/settlement (an award), not a market purchase or a voluntary sale. The withholding of shares to cover taxes is routine and does not necessarily indicate a decision to sell shares on market.
• The sequence recorded—derivative cancellation (D), acquisition of common shares (A), and shares withheld for taxes (F)—is a common way RSU vesting appears on Form 4s (settled in stock with net-share withholding to cover tax obligations).